ym 022 has been researched along with indomethacin in 1 studies
Studies (ym 022) | Trials (ym 022) | Recent Studies (post-2010) (ym 022) | Studies (indomethacin) | Trials (indomethacin) | Recent Studies (post-2010) (indomethacin) |
---|---|---|---|---|---|
65 | 1 | 8 | 29,527 | 1,838 | 3,396 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akuzawa, S; Ito, H; Kamato, T; Kobayashi, A; Miyata, K; Nagakura, Y; Nishida, A; Takinami, Y; Yamano, M; Yuki, H | 1 |
1 other study(ies) available for ym 022 and indomethacin
Article | Year |
---|---|
YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
Topics: Animals; Anti-Ulcer Agents; Benzodiazepines; Duodenal Ulcer; Epirizole; Ethanol; Famotidine; Gastric Acid; Gastric Mucosa; Hydrogen-Ion Concentration; Indomethacin; Male; Omeprazole; Pyloric Antrum; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Stomach Ulcer; Stress, Physiological | 1994 |